These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 11060814)

  • 1. Review of the acetylcholinesterase inhibitor galanthamine.
    Sramek JJ; Frackiewicz EJ; Cutler NR
    Expert Opin Investig Drugs; 2000 Oct; 9(10):2393-402. PubMed ID: 11060814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacology of galanthamine and its analogues.
    Harvey AL
    Pharmacol Ther; 1995; 68(1):113-28. PubMed ID: 8604434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.
    Bores GM; Huger FP; Petko W; Mutlib AE; Camacho F; Rush DK; Selk DE; Wolf V; Kosley RW; Davis L; Vargas HM
    J Pharmacol Exp Ther; 1996 May; 277(2):728-38. PubMed ID: 8627552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galanthamine.
    Fulton B; Benfield P
    Drugs Aging; 1996 Jul; 9(1):60-5; discussion 66-7. PubMed ID: 8818586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.
    Thomsen T; Kewitz H
    Life Sci; 1990; 46(21):1553-8. PubMed ID: 2355800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and new developments with galantamine in the treatment of Alzheimer's disease.
    Tariot P
    Expert Opin Pharmacother; 2001 Dec; 2(12):2027-49. PubMed ID: 11825333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on the pharmacology of galantamine.
    Villarroya M; García AG; Marco-Contelles J; López MG
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution.
    Greenblatt HM; Kryger G; Lewis T; Silman I; Sussman JL
    FEBS Lett; 1999 Dec; 463(3):321-6. PubMed ID: 10606746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
    Lilienfeld S
    CNS Drug Rev; 2002; 8(2):159-76. PubMed ID: 12177686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of New Galantamine Derivatives in a Scopolamine Model of Dementia in Mice.
    Lazarova M; Tancheva L; Alexandrova A; Tsvetanova E; Georgieva A; Stefanova M; Tsekova D; Vezenkov L; Kalfin R; Uzunova D; Petkova-Kirova P
    J Alzheimers Dis; 2021; 84(2):671-690. PubMed ID: 34569967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galantamine in Alzheimer's disease.
    Razay G; Wilcock GK
    Expert Rev Neurother; 2008 Jan; 8(1):9-17. PubMed ID: 18088197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galanthamine, a natural product for the treatment of Alzheimer's disease.
    Marco L; do Carmo Carreiras M
    Recent Pat CNS Drug Discov; 2006 Jan; 1(1):105-11. PubMed ID: 18221196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical and molecular aspects on interactions of galanthamine and its derivatives with cholinesterases.
    Gulcan HO; Orhan IE; Sener B
    Curr Pharm Biotechnol; 2015; 16(3):252-8. PubMed ID: 25483718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galantamine for vascular cognitive impairment.
    Birks J; Craig D
    Cochrane Database Syst Rev; 2006 Jan; (4):CD004746. PubMed ID: 23862185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of galantamine in patients with mild Alzheimer's disease.
    Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
    Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galantamine hydrobromide: an agent for Alzheimer's disease.
    Zarotsky V; Sramek JJ; Cutler NR
    Am J Health Syst Pharm; 2003 Mar; 60(5):446-52. PubMed ID: 12635450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on Alzheimer drugs (galantamine).
    Raskind MA
    Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galantamine for vascular cognitive impairment.
    Craig D; Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD004746. PubMed ID: 16437493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.